the timing and amount of future cash flows. 2.4. CONTRIBUTIONS TO PANTERA SA/NV 
In 2022, IBA established a strategic R&D 
partnership as a Joint Venture with SCK-CEN 
(Belgian Nuclear Research Center). Both 
entities participate for 50% of the share capital 
with an initial contribution of EUR 0.3 million. The JV is established in Belgium and will be 
active in the nuclear medicine, more specifically 
it will develop, produce and distribute the 
isotope Ac.225.